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AbstrAct
Objectives External validity, or generalisability, is 
the measure of how well results from a study pertain 
to individuals in the target population. We assessed 
generalisability, with respect to socioeconomic status, of 
estimates from a matched case–control study of 13-valent 
pneumococcal conjugate vaccine effectiveness for the 
prevention of invasive pneumococcal disease in children 
in the USA.
Design Matched case–control study.
setting Thirteen active surveillance sites for invasive 
pneumococcal disease in the USA.
Participants Cases were identified from active 
surveillance and controls were age and zip code matched.
Outcome measures Socioeconomic status was assessed 
at the individual level via parent interview (for enrolled 
individuals only) and birth certificate data (for both enrolled 
and unenrolled individuals) and at the neighbourhood level 
by geocoding to the census tract (for both enrolled and 
unenrolled individuals). Prediction models were used to 
determine if socioeconomic status was associated with 
enrolment.
results We enrolled 54.6% of 1211 eligible cases and 
found a trend toward enrolled cases being more affluent 
than unenrolled cases. Enrolled cases were slightly 
more likely to have private insurance at birth (p=0.08) 
and have mothers with at least some college education 
(p<0.01). Enrolled cases also tended to come from more 
affluent census tracts. Despite these differences, our best 
predictive model for enrolment yielded a concordance 
statistic of only 0.703, indicating mediocre predictive 
value. Variables retained in the final model were assessed 
for effect measure modification, and none were found to 
be significant modifiers of vaccine effectiveness.
conclusions We conclude that although enrolled 
cases are somewhat more affluent than unenrolled 
cases, our estimates are externally valid with respect to 
socioeconomic status. Our analysis provides evidence 
that this study design can yield valid estimates and the 
assessing generalisability of observational data is feasible, 
even when unenrolled individuals cannot be contacted.
IntrODuctIOn
External validity, or generalisability, is the 
measure of how well results from a study 
pertain to individuals in the target popula-
tion.1–3 Studies may fail to be generalisable 
to a target population when both of the 
following criteria are met: (1) selection/
enrolment into the study is differential with 
respect to variable X (ie, the study population 
is not representative of the source population 
with respect to variable X, which is usually 
a potential confounder) and (2) variable X 
modifies the exposure–outcome relationship 
under study.1 4
Increased external validity can be a major 
benefit of observational studies versus 
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strengths and limitations of this study
 ► Strengths included population-based 
surveillance  data and  multiple data sources for 
estimating socioeconomic status (ie, case report 
form, parent interview and geocoding) at multiple 
levels (individual and neighbourhood).
 ► This was the first study to look at generalisability 
with respect to socioeconomic status in a vaccine 
effectiveness study.
 ► Weaknesses included no access to parent interview 
variables for unenrolled cases, the study potentially 
lacked sufficient power to identify effect measure 
modification, and  no nationwide surveillance to 
compare results.
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randomised controlled trials (RCTs).2–9 Unlike in RCTs, 
where strict exclusion criteria are often used, obser-
vational studies usually enrol a broader subset of the 
population.3 This may be especially true in case–control 
studies, in which researchers commonly attempt to enrol 
every case of disease in a given surveillance population 
(eg, geographic area or hospital system).10 With the 
assumption that the study source population (the surveil-
lance area) does not vary in a meaningful way from the 
target population (eg, an entire country), then results 
from observational studies may be more generalisable 
than those from RCTs.10
Unfortunately, due to issues related to tracking, 
contacting and enrolling participants, generalisability in 
observational studies may not be achieved, even when a 
priori exclusion criteria are minimal. In particular, the 
study population may differ from the source popula-
tion by socioeconomic status (SES), which is frequently 
associated with characteristics that may affect enrolment 
probability.11 For example, less-affluent individuals may 
lack a landline or frequently switch cell phone numbers, 
making them harder to reach; they may hold multiple 
jobs or have long commutes, making them less likely to 
answer their phone; they may have diminished use of or 
trust in the medical system, making them less likely to 
agree to enrolment; they may seek care at underfunded 
(eg, public) hospitals, which lack the resources to enrol 
participants.12–17 Alternatively, lower-SES individuals may 
be more likely to join a study that provides a monetary 
incentive for participating versus those of higher SES for 
whom the monetary incentive is lower.
While not always a problem, lack of representative-
ness by SES may reduce external validity if SES modifies 
the effect of the exposure–outcome relationship under 
study.18–20 One way to explore generalisability as it 
relates to SES is to evaluate differences in SES indicators 
between those selected into a study and those who were 
eligible, but not selected. Although some individual 
SES constructs, such as use of or trust in the medical 
system, may not be measured accurately, others, such 
as educational attainment, are more readily available. 
Additionally, other characteristics, such as recent immi-
gration, insurance status and utilisation of prenatal 
care, can serve as proxies for harder-to-measure SES 
constructs, providing some context for the demographic 
characteristics of the underlying source and participant 
populations.
Extensive SES information is usually not available for 
individuals who are not enrolled in a study. We present 
an analysis of the external validity of estimates from a 
study with access to relatively detailed information on 
unenrolled cases, providing a rare opportunity to assess 
differences in key SES variables between enrolled and 
unenrolled cases. For variables with substantial differ-
ences, we assessed effect measure modification (EMM), 
using data from a large matched case–control study of 
13-valent pneumococcal conjugate vaccine (PCV13).21
MethODs
Parent study and study population
PCV13 was introduced in the USA in 2010 as part of the 
routine childhood immunisation schedule.22
After licensure, the Centers for Disease Control and 
Prevention (CDC) conducted a vaccine effectiveness 
(VE) evaluation in children aged 2–59 months with 
culture dates between 1 May 2010 and 31 May 2014 who 
were identified through the Active Bacterial Core surveil-
lance (ABCs) system or one of three additional sites 
with similar surveillance procedures. This parent study 
has been previously published and is summarised in the 
online supplementary material—Methods for the current 
study.21 In addition to the exclusion criteria for the parent 
study, we excluded cases from two ABCs sites, Colorado 
and Maryland, because the necessary SES data were not 
available from those sites. The total annual surveillance 
population under 5 years of age was 4 249 724.
In the current study, almost 45% of cases were not 
enrolled, leading to concerns about representativeness 
with respect to SES (table 2). Further, past studies of 
invasive pneumococcal disease (IPD) and pneumococcal 
vaccines have provided some evidence for differential risk 
of IPD at different levels of individual SES, potentially due 
to the association of lower SES with IPD risk factors (eg, 
existing chronic or immunocompromising conditions, 
smoking exposure, household crowding).
enrolment procedures
Enrolment procedures have been previously published.21 
Briefly, cases were identified via routine surveillance and 
enrolled over the phone. Lists of eligible controls were 
obtained from local birth registries for children born in 
the same zip code in which the case resided when diag-
nosed with IPD and born within 14 days of the case. 
Detailed information on eligible and enrolled controls 
has been previously published.23 Vaccine providers for 
cases and controls were contacted and state or city immu-
nisation registries were reviewed to obtain vaccine and 
medical histories. Additional details on enrolment proce-
dures have been previously published and are summarised 
in the online supplementary material for the present 
study.21 Both the parent study and the current analysis 
were approved by institutional review boards (IRBs) at 
CDC and surveillance sites. The current analysis was also 
approved by the IRB of the University of North Caroli-
na-Chapel Hill.
covariate assessment
Surveillance staff completed a standard case report form 
(CRF) for every IPD case identified through ABCs.24 
We included the following variables from the CRF (for 
all cases, whether or not enrolled in the parent study, 
table 1): hospitalisation status, length of hospitalisation 
and intensive care unit admission, outcome (survived/
died), presence of an underlying condition that is a 
known risk factor for IPD and insurance status at IPD 
culture.22 24 Hospitalisation and ICU admission were 
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Table 1 Data sources and availability by case/control and enrolment status in a PCV13 vaccine effectiveness study
Data source Enrolled case Unenrolled case Enrolled control
Unenrolled 
control
Case report form ✓ ✓
Parent interview ✓ ✓
Birth certificate ✓ ✓ ✓ ✓
Geocoding/American Community Survey ✓ ✓ ✓ ✓
PCV13, 13-valent pneumococcal conjugate vaccine.
Table 2 Enrolment numbers, reasons for non-enrolment 
and geocoding status for cases of IPD identified in a PCV13 
vaccine effectiveness study
Enrolment status
Cases, n 
(%)
Could not be 
geocoded, n (%)
IPD cases identified 1211† 21 (1.8)
Enrolled 661 (54.6) 9 (1.4)
Not enrolled 550 (45.4) 12 (2.2)
  Could not locate/contact 194 (35.3) 4 (2.1)
  Refused 177 (32.2) 5 (2.8)
  No serotype available 158 (28.7) 2 (1.3)
  Recurrent 11 (2.0) 1 (9.1)
  Vaccine history not 
available
6 (1.1) 0
  Resident of long-term 
care facility
4 (0.7) 0
†Excludes three children originally misclassified as ineligible and 
excluded from this analysis.
IPD, invasive pneumococcal disease; PCV13, 13-valent 
pneumococcal conjugate vaccine.
combined into a three-level severity index: not hospital-
ised, hospitalised but not admitted to ICU and admitted 
to ICU.
Individual-level ses indicators
For cases and controls (regardless of enrolment status, 
table 1), study staff obtained variables from the birth 
certificate,25 including: mother’s race, ethnicity, educa-
tion, source of payment for the birth and timing/
initiation of prenatal care and gestational age, which 
were used to calculate the Adequacy of Prenatal Care 
Utilization (APNCU) Index.26 27 APNCU is a four-cate-
gory variable that summarises how early in the pregnancy 
a woman initiated prenatal care and how many total 
prenatal care visits the woman received compared with 
how many are recommended by the American College 
of Obstetrics and Gynecology for a pregnancy of a given 
length.26 27 Insurance status and APNCU Index were anal-
ysed as measures of the individual’s access to and use of 
the medical system.11
neighbourhood-level ses indicators
All enrolled and unenrolled children were geocoded, 
using a standard geocoding protocol (available from the 
authors on request). For children whose locations could 
not be confirmed, the most recent known address (from 
the birth certificate, state or city immunisation registry 
or medical chart) was used. Census tract data were 
merged with the 2013 5-year estimates from the American 
Community Survey (ACS), an annual survey conducted 
by the US Census Bureau, which includes demographic 
and SES indicators. These census-tract-level estimates can 
be a useful tool for understanding the context in which 
a child lives by complementing individual-level SES indi-
cators.28 29
comparison groups
Importantly, in matched case–control studies, controls 
need not be representative of the source population with 
respect to the matching factor(s). In fact, if matching is 
done correctly, controls should resemble enrolled cases 
on the matching factor. This analysis, therefore, focuses 
on representativeness of enrolled cases with respect to 
eligible cases and leaves questions concerning controls 
for other analyses.23
statistical methods
Exploratory analyses compared differences in individu-
al-level characteristics and ACS variables between enrolled 
and unenrolled cases. We also used the ACS variables to 
calculate a composite index of SES, based on the Socio-
economic Position Index (SEP Index) created by Krieger 
et al for the Public Health Disparities Geocoding Project.30 
The SEP Index measures the major SES constructs of 
wealth, education and occupation at the neighbourhood 
level. Specifically, it includes: working class, unemploy-
ment, poverty, education, home prices and median family 
income (with home prices and median income reversed, 
so a higher SEP score indicates lower SES).31 p Values 
were calculated for continuous and categorical predictors 
via two-sided Wilcoxon rank-sum test and Fisher’s exact 
test, respectively.
Because we had access to many SES-related variables 
through the CRF, birth certificates and ACS, it was not 
practical to assess every variable for EMM. Instead, we 
chose variables to assess for EMM in two ways. First, we 
decided a priori to assess as modifiers the SEP Index and 
the following individual-level variables that had p values 
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Table 3 Characteristics of eligible cases by enrolment 
status:
a) ABCs case report form
Characteristic
Enrolled
(n=661)
Not 
enrolled
(n=550) p Value*
Median age, median 
months (IQR)
21 (11–37) 22 (12–37) 0.27
Child’s race
  White, non-Hispanic 262 (42.2) 217 (43.1) 0.41
  Black, non-Hispanic 157 (25.3) 139 (27.6)
  Other, non-Hispanic 64 (10.3) 55 (10.9)
  Hispanic 138 (22.2) 92 (18.3)
  Unknown 40 47
Insurance status at time 
of IPD culture
  Private 207 (49.9) 205 (47.7) 0.83
  Public 254 (47.0) 208 (48.4)
  Military 2 (0.4) 2 (0.5)
  Uninsured 15 (2.8) 15 (3.5)
  Other/unknown 120 120
Hospitalised 454 (68.8) 354 (66.4) 0.38
  Median length of stay 
in days (IQR)
5 (3–10) 5 (2–10) 0.65
  ICU 124 (31.9) 89 (29.0) 0.46
Survived 648 (98.8) 511 (97.0) 0.04
Chronic condition 9 (1.4) 5 (0.9) 0.59
Immunocompromising 
condition
64 (9.7) 64 (11.6) 0.30
*p Value is from Wilcoxon rank-sum test for continuous variables 
and from Fisher’s exact test for categorical variables.
ABCs, Active Bacterial Core surveillance; ICU, intensive care unit; 
IPD, invasive pneumococcal disease.
<0.2 in the exploratory analyses for differences between 
enrolled and unenrolled: maternal education, insurance 
status at birth and APNCU. Second, to ensure we did 
not miss any variables for the EMM assessment that may 
be strong modifiers and related to representativeness, 
we used predictive modelling to select additional ACS 
variables to assess for EMM. Many of the available ACS 
variables measured similar metrics (both to other ACS 
variables and to the individual variables); therefore, we 
fit a series of models to narrow the selection. All models 
fit were logistic regression, using backward selection and 
retaining variables with a p value of <0.2.
We first fit a single predictive model including all 
individual-level variables (ie, CRF and birth certificate 
variables), requiring the model to retain the following 
CRF variables: severity, outcome, underlying condi-
tion status, child’s race/ethnicity and insurance status 
at IPD culture. This model also included interaction 
terms between child’s race/ethnicity and maternal 
education and between child’s race/ethnicity and 
APNCU. We divided the ACS variables into four cate-
gories—demographics, wealth, work and household 
characteristics—for inclusion in separate models 
to reduce the number of ACS variables used. Four 
models were run, including all individual-level variables 
retained from the first model and each category of the 
ACS variables. Lastly, we fit the final predictive model, 
which included all individual-level variables and interac-
tion terms (regardless of whether they were retained in 
the first model) and any variables retained in the ACS 
models. As with the first model, we required the model 
to retain the CRF variables.
Any variables included in the final model predicting 
enrolment were assessed as potential modifiers, in addi-
tion to the SEP Index and individual-level variables 
chosen a priori. All the individual-level variables were 
already categorical. Variables not applicable to and/
or not available for controls (ie, all CRF variables) were 
excluded. Child’s race/ethnicity, underlying condition 
status and insurance status at IPD were collected as part 
of the parent interview/provider follow-up for enrolled 
children and could therefore be assessed for EMM. The 
ACS variables were continuous, so we dichotomised 
them at the median for the EMM analysis (online supple-
mentary table). To assess variables as modifiers, we fit 
conditional logistic regression models for each variable 
with IPD caused by 1 of the 13 serotypes included in the 
vaccine as the outcome, receipt of one or more doses of 
PCV13 as the exposure and an interaction term between 
each variable of interested and PCV13 receipt.21 Because 
power to assess interaction terms is reduced, we used a p 
value <0.2 as our cut-off for the likelihood ratio χ2 value 
for the interaction term and then did a Bonferroni adjust-
ment by the total number of variables assessed for EMM 
to account for multiple comparisons. Therefore, α<0.015 
for the likelihood ratio test was considered an indication 
of modification and cause for concern about generalis-
ability.
results
Enrolment
The annual population of children under age 5 in the 
catchment area for the parent study was approximately 
4.7 million, which was reduced to 4.2 million with the 
exclusion of Colorado and Maryland. We identified 1214 
cases of IPD in children in the catchment area for this 
analysis. Three children were initially miscategorised as 
ineligible by surveillance personnel and enrolment was 
not attempted, leaving 1211 cases in our analysis, 661 
(54.6%) of whom were enrolled (table 2). Of the 550 
cases not enrolled, 194 (35.3%) could not be located/
contacted, 177 (32.2%) refused and 158 (28.7%) did not 
have a pneumococcal isolate available for serotyping. 
The remaining 21 children were not enrolled for other 
reasons.
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Table 3 b) Birth certificate variables
Characteristic
Enrolled
(n=661)
Not enrolled
(n=550) p Value*
Maternal race/ethnicity, n (%)
  White, non-Hispanic 268 (46.7) 206 (44.8) 0.22
  Black, non-Hispanic 127 (22.1) 127 (27.6)
  Hispanic 52 (9.1) 36 (7.8)
  Other, non-Hispanic 127 (22.1) 91 (19.8)
  Unknown 87 90
Maternal education level, n (%)
  Less than high school 110 (20.2) 99 (22.7) <0.01
  High school or equivalent 130 (23.9) 136 (31.2)
  Some college 146 (26.8) 115 (26.4)
  College degree or more 158 (29.0) 86 (19.7)
  Unknown 117 114
Source of payment for birth, n (%)
  Private 228 (48.2) 151 (39.8) 0.08
  Public/state 223 (47.2) 209 (55.2)
  Uninsured 8 (1.7) 9 (2.4)
  Other 14 (3.0) 10 (2.6)
  Unknown 188 171
Adequacy of Prenatal Care Utilization, n (%)
  Adequate plus 183 (34.9) 135 (32.8) 0.16
  Adequate 186 (35.5) 157 (38.1)
  Intermediate 67 (12.8) 37 (9.0)
  Inadequate 88 (16.8) 83 (20.2)
  Unknown 137 138
Gestational age, median weeks (IQR)† 39 (38–40) 39 (38–40) 0.57
Prenatal care initiation, median month (IQR)† 2 (2–3) 3 (2–4) 0.01
Total prenatal care visits, median (IQR)† 12 (10–16) 12 (10–18) 0.94
*p Value is from Wilcoxon rank-sum test for continuous variables and from Fisher’s exact test for categorical variables.
†Included in calculation of Adequacy of Prenatal Care Utilization Index.26 27
Differences between enrolled and unenrolled cases
Enrolled and unenrolled cases were of similar age (median 
age: 21 and 22 months, respectively) and race/ethnicity 
(42% and 43% white, non-Hispanic, respectively, p=0.41; 
table 3a). Enrolled children were slightly more likely to 
survive their illness (98.8% vs 97.0%, p=0.04).
Mothers of enrolled and unenrolled children had a 
similar racial/ethnic distribution (table 3b). Maternal 
education was somewhat different between the two groups, 
with 44.1% of mothers of enrolled children having no 
college education compared with 53.9% of mothers of 
unenrolled children (p<0.01).
The SEP Index was similar in enrolled and unenrolled 
cases (p=0.07; table 3c). A number of characteristics 
differed between the two groups, including proportion 
with an income above US$60 000, proportion disabled and 
proportion of households occupied (p<0.01 for all).
enrolment prediction model
In the individual-level model, three variables—maternal 
education, APNCU and the interaction between race/
ethnicity and maternal education—were retained in addi-
tion to the five variables that we required (table 4). The 
model yielded a concordance (c-) statistic of 0.639, indi-
cating only marginal predictive ability (0.5 is equal to a 
coin flip).32 Retaining these eight variables and adding 
demographic, wealth, work and household variables 
from the ACS yielded similarly low c- statistics of 0.632, 
0.652, 0.643 and 0.655, respectively. The final predictive 
model included IPD severity, outcome, underlying condi-
tion status, child’s race/ethnicity, insurance status at IPD 
culture, maternal education, APNCU, race/ethnicity and 
maternal education interaction, as well as the following 
census tract variables: per cent of tract of white race, 
earning <US$30 000, earning ≥US$60 000, disabled, 
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Table 3 c) American Community Survey
Characteristic
Enrolled
(n=661)
Not enrolled
(n=550) p Value (univariate)*
p Value 
(multivariable model)
Successfully geocoded, n (%) 652 (98.6) 538 (97.8) 0.28 N/A
White race 56.1 (17.6–81.9) 58.9 (19.8–83.9) 0.26 <0.01
Household income <US$30 000 28.1 (17.3–38.5) 29.9 (18.9–42.1) 0.03 <0.01
Household income ≥US$60 000 41.1 (29.4–57.8) 38.2 (25.1–53.8) <0.01 <0.01
Mean hours worked (annually) 38.1 (36.8–39.3) 38.0 (36.7–39.2) 0.39 0.05
Disabled workers 10.1 (7.5–13.5) 11.2 (8.2–16.0) <0.01 <0.01
Working class 60.3 (52.6–69.8) 62.3 (52.5–69.8) 0.36 <0.01
Occupied houses 92.4 (88.1–95.8) 91.3 (86.4–94.7) <0.01 0.07
SEP Index†, median (IQR) 1.5 (−1.4–4.5) 2.1 (−0.8–4.9) 0.07 N/A
Unless otherwise noted, all measurements are the median per cent (IQR) by census tract.
*p Value is from Wilcoxon rank-sum test for continuous variables and from Fisher’s exact test for categorical variables.
†Socioeconomic Position Index. Higher value indicates higher level of deprivation.30
N/A, not applicable.
Table 4 Prediction models for case enrolment
Mode
Variables in model (n)
AIC c-statisticStart After selection
Individual level 11 7 (IPD severity, outcome, underlying condition status, race/ethnicity, 
insurance at the time of IPD culture, maternal education, race/
ethnicity×maternal education)
717.840 0.639
ACS: demographics 26 9 (individual level from above+per cent: white race, speaks English) 927.995 0.632
ACS: wealth 18 11 (individual level from above+per cent: living abroad 1 year ago, 
earning <US$30 000, earning ≥US$60 000, per capita income)
927.838 0.652
ACS: work 16 10 (individual level from above+per cent: mean hours worked, 
disabled, working class)
932.599 0.643
ACS: household 30 14 (individual level from above+per cent: owner-occupied 
housing units, households with one resident, households without 
children <18 years, crowded households, households with plumbing, 
households with kitchens, occupied housing units)
896.747 0.655
Final (all 
individual level, 
plus retained ACS 
variables)
27 15 (individual level from above+APNCU Index, per cent: white race, 
earning <US$30 000, earning ≥US$60 000, disabled, working class, 
occupied houses, mean hours worked)
690.606 0.703
ACS, American Community Survey; AIC, Akaike information criterion; APNCU, Adequacy of Prenatal Care Utilization; IPD, 
invasive pneumococcal disease.
working class, occupied households and mean hours 
worked. This model had a concordance statistic of 0.703, 
indicating only slightly better predictive ability than the 
single ACS category models.
effect measure modification
None of the individual-level variables retained in the 
prediction model were found to be significant modifiers 
of the effect of PCV13 receipt on IPD caused by 1 of the 
13 serotypes in the vaccine (figure 1A). Likewise, none 
of the ACS variables (including SEP Index) assessed as 
modifiers had a p value <0.015 for the likelihood ratio 
test (figure 1B).
DIscussIOn
We assessed the external validity of VE estimates from 
a postlicensure evaluation of PCV13 in children in the 
USA. Despite a small trend toward enrolled cases being 
more affluent than unenrolled cases, the differences 
were minimal and most did not meet a priori defini-
tions of significance. Additionally, we did not find EMM 
of VE by any SES variables and therefore conclude that 
lack of generalisability to the broader source population 
is of minimal concern in the current study. Our results 
provide some evidence that study designs based on popu-
lation-based surveillance systems can be generalisable, 
even with relatively low case enrolment (54.6% in the 
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Figure 1 Vaccine effectiveness (and 80% CIs) for characteristics retained in the final predictive model, stratified as indicated. 
(A) Individual-level variables; (B) American Community Survey variables, divided at median. IPD, invasive pneumococcal disease; 
SEP, Socioeconomic Position Index; SES, socioeconomic status.
current study)—in particular, when researchers conduct 
extensive investigations to obtain contact information 
and provide incentives to encourage enrolment.
Generalisability can be a major benefit of observa-
tional vaccine studies over RCTs8 33; however, it is rare for 
reports on either study type to provide extensive infor-
mation on how their study population differs from their 
source or target population.1 34 We used a novel approach 
to assessing generalisability with respect to SES, exploring 
a mix of variables chosen a priori and through predictive 
modelling. We had access to more detailed information 
on unenrolled cases than is typical; however, the data we 
assessed were collected without patient contact and there-
fore could be gathered more routinely in observational 
studies. Our analysis shows that assessing and reporting 
on generalisability may be feasible even when it is not 
possible to interview unenrolled cases.
Postlicensure VE studies are common tools to assess the 
‘real-world’ effectiveness of vaccines, and as with similar 
studies, cases were identified from a disease surveillance 
system.35–38 Generalisability of results with respect to 
SES from vaccine studies is an important component of 
assessing the overall quality of a study, as well as the utility 
of results beyond the study population. Thus, although 
we found little cause for concern in the current analysis, 
this conclusion may not be applicable for vaccines for 
diseases, such as rotavirus, which are spread differently 
and therefore may have different risk factors and poten-
tial modifiers. Likewise, if case identification or enrolment 
methods are different, representativeness to the source 
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population could be lacking. Since SES has been 
identified as a significant risk factor for many vaccine-pre-
ventable diseases, other postlicensure vaccine studies may 
find more substantial cause for concern. However, careful 
selection of case and control populations, regardless of 
the disease under study, can yield results, such as these, 
which are generalisable to the underlying source popu-
lation.
Our study had some limitations. We did not have 
access to variables collected during the parent inter-
view (eg, household income) for unenrolled cases and 
so could not explore differences between enrolled and 
unenrolled cases for these variables. We may have also 
lacked sufficient power to identify EMM in our study. 
For example, the confidence limits for VE among those 
without insurance were extremely wide. Likewise, a VE 
study of the 7-valent pneumococcal conjugate vaccine (a 
more limited valency, but otherwise identical, vaccine) in 
a similar population to the current analysis found clear 
evidence of EMM by underlying condition status.37 We 
did not identify EMM by underlying condition status but 
only had two matched sets with underlying conditions and 
discordant vaccination status (required to contribute to a 
conditional analysis) in our study. Additionally, we were 
not able to compare cases eligible for our study (ie, the 
source population) with cases throughout the USA (ie, 
the target population) because active, population-based 
surveillance for IPD does not exist nationwide.
We identified minimal external validity concerns in a 
PCV13 VE study in children in the USA. Nevertheless, 
future VE studies should take care to enrol as broad a 
subset of cases as possible, especially focusing on children 
from lower-SES areas. Additionally, every effort should 
be made to gather at least basic SES information so that 
study populations can be compared with source popula-
tions and estimates can be understood in context.
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